蓝帆医疗(002382.SZ)：心脑血管业务子公司蓝帆柏盛拟引入战投融资9亿元

智通财经网01-25

蓝帆医疗(002382.SZ)公告，公司的心脑血管业务主体、全资子公司北京蓝帆柏盛医疗科技有限公司(“蓝帆柏盛”)拟引入战略投资者首都大健康产业(北京)基金(有限合伙)、河北临空私募基金管理有限公司及临朐县高新技术产业投资有限公司(合称“投资方”)进行增资扩股，投资方拟按照40亿元的投前估值以现金方式向蓝帆柏盛增资金额合计人民币9亿元，对应交易后蓝帆柏盛全部股权的18.3673%。增资完成后，公司...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2406135742?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-01-25 21:21","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2406135742","market":"fut","top_or_hot":-1,"title":"蓝帆医疗(002382.SZ)：心脑血管业务子公司蓝帆柏盛拟引入战投融资9亿元","media":"智通财经网","content":"<div>\n<p>蓝帆医疗(002382.SZ)公告，公司的心脑血管业务主体、全资子公司北京蓝帆柏盛医疗科技有限公司(“蓝帆柏盛”)拟引入战略投资者首都大健康产业(北京)基金(有限合伙)、河北临空私募基金管理有限公司及临朐县高新技术产业投资有限公司(合称“投资方”)进行增资扩股，投资方拟按照40亿元的投前估值以现金方式向蓝帆柏盛增资金额合计人民币9亿元，对应交易后蓝帆柏盛全部股权的18.3673%。增资完成后，公司...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-25/doc-inaeuezu0876114.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>蓝帆医疗(002382.SZ)：心脑血管业务子公司蓝帆柏盛拟引入战投融资9亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n蓝帆医疗(002382.SZ)：心脑血管业务子公司蓝帆柏盛拟引入战投融资9亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-25 21:21 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-25/doc-inaeuezu0876114.shtml><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>蓝帆医疗(002382.SZ)公告，公司的心脑血管业务主体、全资子公司北京蓝帆柏盛医疗科技有限公司(“蓝帆柏盛”)拟引入战略投资者首都大健康产业(北京)基金(有限合伙)、河北临空私募基金管理有限公司及临朐县高新技术产业投资有限公司(合称“投资方”)进行增资扩股，投资方拟按照40亿元的投前估值以现金方式向蓝帆柏盛增资金额合计人民币9亿元，对应交易后蓝帆柏盛全部股权的18.3673%。增资完成后，公司...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-25/doc-inaeuezu0876114.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002382","symbol_name":"蓝帆医疗","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-25/doc-inaeuezu0876114.shtml","article_id":"2406135742","we_media_id":null,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-25/doc-inaeuezu0876114.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2406135742","pubTimestamp":1706188860,"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"蓝帆医疗公告，公司的心脑血管业务主体、全资子公司北京蓝帆柏盛医疗科技有限公司拟引入战略投资者首都大健康产业(北京)基金、河北临空私募基金管理有限公司及临朐县高新技术产业投资有限公司进行增资扩股，投资方拟按照40亿元的投前估值以现金方式向蓝帆柏盛增资金额合计人民币9亿元，对应交易后蓝帆柏盛全部股权的18.3673%。增资完成后，公司持有蓝帆柏盛的股权比例将由100%变更为81.6327%。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"002382":"蓝帆医疗","BK0114":"健康中国","BK0251":"专用设备","BK0077":"质押式回购"},"translate_title":"Lan Fan Medical (002382. SZ): Lan Fan Baisheng, a subsidiary of cardiovascular and cerebrovascular business, plans to introduce war investment and financing of 900 million yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002382":1},"content_text":"蓝帆医疗(002382.SZ)公告，公司的心脑血管业务主体、全资子公司北京蓝帆柏盛医疗科技有限公司(“蓝帆柏盛”)拟引入战略投资者首都大健康产业(北京)基金(有限合伙)、河北临空私募基金管理有限公司及临朐县高新技术产业投资有限公司(合称“投资方”)进行增资扩股，投资方拟按照40亿元的投前估值以现金方式向蓝帆柏盛增资金额合计人民币9亿元，对应交易后蓝帆柏盛全部股权的18.3673%。增资完成后，公司持有蓝帆柏盛的股权比例将由100%变更为81.6327%。同时，公司作为创始股东在本次增资交割前可以按照投资方批准的方案将自身对蓝帆柏盛的债权实施6-8亿元的债转股，本次增资扩股及债转股完成后，蓝帆柏盛的投后估值将为55-57亿元，公司对蓝帆柏盛的持股比例在83.64%-84.21%之间。据悉，子公司蓝帆柏盛本次增资引入战略投资者，一方面优化了股权结构，借助大健康领域产业基金、国资投资平台优势资源，获取优质的产业资源，形成资本与产业链的协同效应;另一方面，本次增资结合蓝帆柏盛自身发展需要和资本运作规划的综合考虑，有助于补充提供经营发展所需资金，加速在高端创新医疗器械市场的开拓。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2406135742"}